Tags Archive Navigation
icon
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
-
Media ReleaseSandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
-
StoryWhen you think of the word ‘cancer’, what are the first words that spring to mind?
-
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
-
Media ReleaseNovartis resumes production and delivery of radioligand therapy medicines ahead of schedule
-
Media ReleaseNew Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
-
Media ReleaseNovartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
-
Media ReleaseNovartis presents new data in breast and prostate cancer at ESMO
-
Media ReleaseNovartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial
-
Media ReleaseNovartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 14
- › Next page